First‐time‐in‐human randomized clinical trial in healthy volunteers and haemodialysis patients with SNF472, a novel inhibitor of vascular calcification

Aims SNF472 is a calcification inhibitor being developed for the treatment of cardiovascular calcification in haemodialysis (HD) and in calciphylaxis patients. This study investigated the safety, tolerability and pharmacokinetics (PK) of intravenous (IV) SNF472 in healthy volunteers (HV) and HD pati...

Full description

Saved in:
Bibliographic Details
Published in:British journal of clinical pharmacology 2018-12, Vol.84 (12), p.2867-2876
Main Authors: Perelló, J., Joubert, P.H., Ferrer, M.D., Canals, A.Z., Sinha, S., Salcedo, C.
Format: Article
Language:English
Subjects:
Adult
Aged
Calcium - metabolism
cardiovascular calcification
Double-Blind Method
end‐stage renal disease
haemodialysis
Healthy Volunteers
Humans
hydroxyapatite
Kidney Failure, Chronic - complications
Kidney Failure, Chronic - therapy
Male
Middle Aged
Original
phytate
Phytic Acid - adverse effects
Phytic Acid - pharmacokinetics
Phytic Acid - pharmacology
Renal Dialysis - adverse effects
SNF472
Vascular Calcification - prevention & control
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Aims SNF472 is a calcification inhibitor being developed for the treatment of cardiovascular calcification in haemodialysis (HD) and in calciphylaxis patients. This study investigated the safety, tolerability and pharmacokinetics (PK) of intravenous (IV) SNF472 in healthy volunteers (HV) and HD patients. Methods This is a first‐time‐in‐human, double‐blind, randomized, placebo‐controlled Phase I study to assess the safety, tolerability and PK of SNF472 after ascending single IV doses in HV and a single IV dose in HD patients. A pharmacodynamic analysis was performed to assess the capability of IV SNF472 to inhibit hydroxyapatite formation. Results Twenty HV and eight HD patients were enrolled. The starting dose in HV was 0.5 mg kg–1 and the dose ascended to 12.5 mg kg–1. The dose selected for HD patients was 9 mg kg–1. Safety analyses support the safety and tolerability of IV SNF472 in HD patients and HV. Most treatment‐emergent adverse events were mild in intensity. No clinically significant effects were observed on vital signs or laboratory tests. PK results were similar in HD patients and HV and indicate a lack of significant dialysability. Pharmacodynamic analyses demonstrated that SNF472 administration reduced hydroxyapatite crystallization potential in HD patients who received IV SNF472 9 mg kg–1 by 80.0 ± 2.4% (mean ± standard error of the mean, 95% CI, 75.3–84.8) compared to placebo (8.7 ± 21.0%, P 
ISSN:0306-5251
1365-2125
DOI:10.1111/bcp.13752